Is ANAB or MAZE more profitable?

ANAB runs the higher net margin — ANAB at 82.37% versus MAZE at -667.95%.

AnaptysBio, Inc. (ANAB) vs Maze Therapeutics, Inc. (MAZE)

A side-by-side comparison of AnaptysBio, Inc. and Maze Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ANAB

AnaptysBio, Inc.

$1.44B

$48.53HealthcareDelayed quote: Oct 6, 2026, 11:50 AM EDT

MAZE

Maze Therapeutics, Inc.

$1.47B

$26.64HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT

Total return — ANAB vs MAZE

growth of $100 · dividends reinvested · last 2y

ANAB +323.8% (+105.9%/yr)MAZE +65.7% (+28.7%/yr)ANAB compounded faster over this window

ANAB MAZE

ANAB vs MAZE: by the numbers

•MAZE is the larger company ($1.47B vs $1.44B market cap).
•ANAB is profitable (82.37% net margin) while MAZE runs a net loss (-667.95%).

Metrics side by side

Valuation

Metric	ANAB	MAZE
P/E ratio	9.04	N/A
P/S ratio	6.05	73.72
P/B ratio	135.73	3.25
EV / EBITDA	11.58	N/A
FCF yield	1.26%	N/A

Profitability

Metric	ANAB	MAZE
Gross margin	98.97%	0.00%
Operating margin	20.42%	0.00%
Net margin	82.37%	-667.95%
ROE	1849.06%	-29.48%
ROIC	47.55%	-28.63%

Growth (annualized)

Metric	ANAB	MAZE
Revenue CAGR (5Y)	18.60%	N/A
FCF CAGR (5Y)	27.41%	N/A
Total return CAGR (5Y)	21.54%	N/A

Frequently asked

Is ANAB or MAZE more profitable?: ANAB runs the higher net margin — ANAB at 82.37% versus MAZE at -667.95%.

Go deeper

Full ANAB analysis Full MAZE analysis Interactive comparison tool

Dig into the metrics

AnaptysBio P/E ratio AnaptysBio ROE Maze Therapeutics ROE AnaptysBio operating margin Maze Therapeutics operating margin AnaptysBio revenue growth Maze Therapeutics revenue growth AnaptysBio free cash flow Maze Therapeutics free cash flow

AnaptysBio & Maze Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest ROIC Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.